Loxo Oncology, Inc. (NASDAQ:LOXO) VP Jennifer Burstein sold 1,500 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $87.50, for a total value of $131,250.00. Following the sale, the vice president now directly owns 1,500 shares of the company’s stock, valued at $131,250. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Jennifer Burstein also recently made the following trade(s):

  • On Thursday, December 14th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The stock was sold at an average price of $83.27, for a total value of $141,559.00.
  • On Monday, November 27th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The stock was sold at an average price of $74.82, for a total value of $127,194.00.
  • On Monday, October 30th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The stock was sold at an average price of $87.19, for a total value of $148,223.00.

Loxo Oncology, Inc. (NASDAQ:LOXO) opened at $96.83 on Friday. The stock has a market capitalization of $2,900.00, a P/E ratio of -16.67 and a beta of 2.54. Loxo Oncology, Inc. has a one year low of $36.75 and a one year high of $98.00.

Loxo Oncology (NASDAQ:LOXO) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.26. analysts anticipate that Loxo Oncology, Inc. will post -5.91 EPS for the current year.

Several hedge funds have recently modified their holdings of LOXO. Lord Abbett & CO. LLC raised its stake in shares of Loxo Oncology by 372.0% during the 2nd quarter. Lord Abbett & CO. LLC now owns 739,540 shares of the biopharmaceutical company’s stock worth $59,304,000 after buying an additional 582,862 shares in the last quarter. FMR LLC increased its stake in Loxo Oncology by 12.1% in the 2nd quarter. FMR LLC now owns 4,394,827 shares of the biopharmaceutical company’s stock valued at $352,420,000 after purchasing an additional 472,814 shares in the last quarter. BlackRock Inc. increased its stake in Loxo Oncology by 20.6% in the 2nd quarter. BlackRock Inc. now owns 1,602,885 shares of the biopharmaceutical company’s stock valued at $128,534,000 after purchasing an additional 273,291 shares in the last quarter. Voya Investment Management LLC increased its stake in Loxo Oncology by 3,757.2% in the 2nd quarter. Voya Investment Management LLC now owns 236,177 shares of the biopharmaceutical company’s stock valued at $18,939,000 after purchasing an additional 230,054 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Loxo Oncology by 24.7% in the 2nd quarter. Vanguard Group Inc. now owns 914,719 shares of the biopharmaceutical company’s stock valued at $73,351,000 after purchasing an additional 181,471 shares in the last quarter. 99.98% of the stock is owned by institutional investors and hedge funds.

A number of research firms have weighed in on LOXO. BidaskClub raised Loxo Oncology from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 12th. Citigroup decreased their price objective on Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a research report on Thursday, November 16th. Morgan Stanley reissued an “overweight” rating and set a $103.00 target price (up from $95.00) on shares of Loxo Oncology in a research note on Friday, October 6th. BTIG Research reissued a “buy” rating and set a $102.00 target price (up from $75.00) on shares of Loxo Oncology in a research note on Friday, September 29th. Finally, JMP Securities raised Loxo Oncology from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $77.18 to $95.00 in a research note on Tuesday, November 14th. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $90.57.

TRADEMARK VIOLATION WARNING: “Loxo Oncology, Inc. (LOXO) VP Sells $131,250.00 in Stock” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2018/01/21/loxo-oncology-inc-loxo-vp-sells-131250-00-in-stock.html.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.